{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:07:28Z","timestamp":1779383248502,"version":"3.53.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The International Journal of Biochemistry & Cell Biology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.biocel.2022.106230","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T19:28:04Z","timestamp":1653161284000},"page":"106230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer"],"prefix":"10.1016","volume":"147","author":[{"given":"Chloe","family":"Gulliver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George S.","family":"Baillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.biocel.2022.106230_bib1","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.biocel.2022.106230_bib2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/15384101.2017.1312236","article-title":"Susceptibility of ATM-deficient pancreatic cancer cells to radiation","volume":"16","author":"Ayars","year":"2017","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/j.biocel.2022.106230_bib3","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1093\/nar\/gkv160","article-title":"Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation","volume":"43","author":"Bakr","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.biocel.2022.106230_bib4","first-page":"62","article-title":"Androgen action in prostate function and disease","volume":"6","author":"Banerjee","year":"2018","journal-title":"Am. J. Clin. Exp. Urol."},{"issue":"1","key":"10.1016\/j.biocel.2022.106230_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(00)80086-0","article-title":"Atm-deficient mice: a paradigm of ataxia telangiectasia","volume":"86","author":"Barlow","year":"1996","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.biocel.2022.106230_bib6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.biocel.2022.106230_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13046-018-0705-7","article-title":"New therapeutic strategies to treat human cancers expressing mutant p53 proteins","volume":"37","author":"Blandino","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biocel.2022.106230_bib8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1101\/gad.14.4.397","article-title":"ATR disruption leads to chromosomal fragmentation and early embryonic lethality","volume":"14","author":"Brown","year":"2000","journal-title":"Genes Dev."},{"issue":"15","key":"10.1016\/j.biocel.2022.106230_bib9","article-title":"Current knowledge of the potential links between inflammation and prostate cancer","volume":"20","author":"Cai","year":"2019","journal-title":"Int. J. Mol. Sci. Multidiscip."},{"key":"10.1016\/j.biocel.2022.106230_bib10","unstructured":"Cancer Research UK , 2018. Prostate cancer mortality statistics. Available at: \u3008https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer\/mortality#heading-Zero\u3009 (Accessed: 9 January 2020)."},{"key":"10.1016\/j.biocel.2022.106230_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2017.08.013","article-title":"DNA damage response inhibitors: mechanisms and potential applications in cancer therapy","volume":"60","author":"Carrassa","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.biocel.2022.106230_bib12","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"\u2018PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biocel.2022.106230_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24341-z","article-title":"DHX9-dependent recruitment of BRCA1 to RNA promotes DNA end resection in homologous recombination","volume":"12","author":"Chakraborty","year":"2021","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.biocel.2022.106230_bib14","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1038\/emboj.2009.294","article-title":"ATM activates p53 by regulating MDM2 oligomerization and E3 processivity","volume":"28","author":"Cheng","year":"2009","journal-title":"EMBO J."},{"issue":"7","key":"10.1016\/j.biocel.2022.106230_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cancergen.2011.05.002","article-title":"Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study","volume":"204","author":"Cheng","year":"2011","journal-title":"Cancer Genet."},{"issue":"8","key":"10.1016\/j.biocel.2022.106230_bib16","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM mutations in cancer: therapeutic implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"26","key":"10.1016\/j.biocel.2022.106230_bib17","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1038\/onc.2013.275","article-title":"ATM signalling and cancer","volume":"33","author":"Cremona","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.biocel.2022.106230_bib18","series-title":"Cancer and Metastasis Reviews","first-page":"413","article-title":"Androgen receptor signaling in prostate cancer","author":"Culig","year":"2014"},{"issue":"9","key":"10.1016\/j.biocel.2022.106230_bib19","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41416-020-1016-2","article-title":"Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models","volume":"123","author":"Dunlop","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"24","key":"10.1016\/j.biocel.2022.106230_bib20","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.20.00046","article-title":"Implementation of germline testing for prostate cancer: Philadelphia prostate cancer consensus conference 2019","volume":"38","author":"Giri","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.biocel.2022.106230_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143415","article-title":"Intersection of two checkpoints: could inhibiting the DNA damage response checkpoint rescue immune checkpoint-refractory cancer?","volume":"13","author":"Goff","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biocel.2022.106230_bib22","doi-asserted-by":"crossref","first-page":"107518","DOI":"10.1016\/j.pharmthera.2020.107518","article-title":"Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): clinical candidate for cancer therapy","volume":"210","author":"Gorecki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biocel.2022.106230_bib23","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biocel.2022.106230_bib24","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.immuni.2015.01.012","article-title":"DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity","volume":"42","author":"H\u00e4rtlova","year":"2015","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.biocel.2022.106230_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12030687","article-title":"ATM-deficient cancers provide new opportunities for precision oncology","volume":"12","author":"Jette","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.biocel.2022.106230_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s42764-020-00011-0","article-title":"ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738","volume":"1","author":"Jette","year":"2020","journal-title":"Genome Instab. Dis."},{"issue":"16","key":"10.1016\/j.biocel.2022.106230_bib27","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1101\/gad.1815309","article-title":"The combined status of ATM and p53 link tumor development with therapeutic response","volume":"23","author":"Jiang","year":"2009","journal-title":"Genes Dev."},{"issue":"24","key":"10.1016\/j.biocel.2022.106230_bib28","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1158\/0008-5472.CAN-12-1667","article-title":"Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition","volume":"72","author":"Kalev","year":"2012","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.biocel.2022.106230_bib29","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.euo.2020.12.001","article-title":"Rare germline variants in ATM predispose to prostate cancer: a PRACTICAL consortium study","volume":"4","author":"Karlsson","year":"2021","journal-title":"Eur. Urol. Oncol."},{"issue":"21","key":"10.1016\/j.biocel.2022.106230_bib30","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular pathways: targeting ATR in cancer therapy","volume":"21","author":"Karnitz","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"7015","key":"10.1016\/j.biocel.2022.106230_bib31","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.biocel.2022.106230_bib32","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1158\/1078-0432.CCR-20-0764","article-title":"Genomic and clinicopathologic characterization of ATM-deficient prostate cancer","volume":"26","author":"Kaur","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.biocel.2022.106230_bib33","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"issue":"5721","key":"10.1016\/j.biocel.2022.106230_bib34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1126\/science.1108297","article-title":"ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex","volume":"308","author":"Lee","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.biocel.2022.106230_bib35","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.3389\/fphar.2020.629266","article-title":"DNA repair pathways in cancer therapy and resistance\u2019","volume":"11","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"25","key":"10.1016\/j.biocel.2022.106230_bib36","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","article-title":"Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells","volume":"39","author":"Lloyd","year":"2020","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.biocel.2022.106230_bib37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41416-020-01114-x","article-title":"Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer","volume":"124","author":"Lozano","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.biocel.2022.106230_bib38","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Mar\u00e9chal","year":"2013","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"18","key":"10.1016\/j.biocel.2022.106230_bib39","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biocel.2022.106230_bib40","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5828","key":"10.1016\/j.biocel.2022.106230_bib41","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1140321","article-title":"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage","volume":"316","author":"Matsuoka","year":"2007","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biocel.2022.106230_bib42","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1541-7786.MCR-14-0240","article-title":"A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function","volume":"13","author":"Menezes","year":"2015","journal-title":"Mol. Cancer Res."},{"issue":"4","key":"10.1016\/j.biocel.2022.106230_bib43","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, a novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.biocel.2022.106230_bib44","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death","volume":"71","author":"Na","year":"2017","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.biocel.2022.106230_bib45","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2020.10.029","article-title":"Advanced prostate cancer with ATM Loss: PARP and ATR inhibitors","volume":"79","author":"Neeb","year":"2021","journal-title":"Eur. Urol."},{"issue":"16","key":"10.1016\/j.biocel.2022.106230_bib46","doi-asserted-by":"crossref","first-page":"9092","DOI":"10.1073\/pnas.161281798","article-title":"ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation","volume":"98","author":"Nghiem","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biocel.2022.106230_bib47","article-title":"Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer","author":"Nientiedt","year":"2021","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"issue":"5","key":"10.1016\/j.biocel.2022.106230_bib48","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.biocel.2022.106230_bib49","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","article-title":"ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer","volume":"80","author":"Rafiei","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.biocel.2022.106230_bib50","doi-asserted-by":"crossref","first-page":"25522","DOI":"10.1074\/jbc.M115.671404","article-title":"ATM inhibition potentiates death of androgen receptor-inactivated prostate cancer cells with telomere dysfunction","author":"Reddy","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.biocel.2022.106230_bib51","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.biocel.2022.106230_bib52","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm.2017.67","article-title":"The essential kinase ATR: ensuring faithful duplication of a challenging genome","volume":"18","author":"Saldivar","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.biocel.2022.106230_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/embj.2020104400","article-title":"Phosphoproteomics reveals novel modes of function and inter\u2010relationships among PIKKs in response to genotoxic stress","volume":"40","author":"Schlam\u2010Babayov","year":"2021","journal-title":"EMBO J."},{"key":"10.1016\/j.biocel.2022.106230_bib54","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.gde.2021.07.003","article-title":"An extending ATR\u2013CHK1 circuitry: the replication stress response and beyond","volume":"71","author":"Simoneau","year":"2021","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.biocel.2022.106230_bib55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM\u2013Chk2 and ATR\u2013Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.biocel.2022.106230_bib56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.nucmedbio.2021.03.009","article-title":"The ATM\u2013Chk2 and ATR\u2013Chk1 pathways in DNA damage signaling and cancer","volume":"96\u201397","author":"Staniszewska","year":"2021","journal-title":"Nucl. Med. Biol."},{"issue":"4","key":"10.1016\/j.biocel.2022.106230_bib57","first-page":"455","article-title":"Inflammation in prostate cancer progression and therapeutic targeting","volume":"4","author":"Stark","year":"2015","journal-title":"Transl. Androl. Urol."},{"issue":"MAR","key":"10.1016\/j.biocel.2022.106230_bib58","first-page":"1","article-title":"The ATM signaling network in development and disease","volume":"4","author":"Stracker","year":"2013","journal-title":"Front. Genet."},{"issue":"7","key":"10.1016\/j.biocel.2022.106230_bib59","first-page":"1307","article-title":"Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing","volume":"8","author":"Sun","year":"2018","journal-title":"Am. J. Cancer Res."},{"issue":"17","key":"10.1016\/j.biocel.2022.106230_bib60","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","article-title":"ATR inhibition induces CDK1-SPOP signaling and enhances anti-PD-L1 cytotoxicity in prostate cancer","volume":"27","author":"Tang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biocel.2022.106230_bib61","unstructured":"U.S. Food and Drug Administration (2020a) FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer, \u3008https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer\u3009. Available at: \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer\u3009 (Accessed: 24 January 2022)."},{"key":"10.1016\/j.biocel.2022.106230_bib62","unstructured":"U.S. Food and Drug Administration (2020b) FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer, \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate\u3009. Available at: \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate\u3009 (Accessed: 24 January 2022)."},{"issue":"2","key":"10.1016\/j.biocel.2022.106230_bib63","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tranon.2017.01.007","article-title":"ATM-deficient colorectal cancer cells are sensitive to the PARP inhibitor olaparib","volume":"10","author":"Wang","year":"2017","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.biocel.2022.106230_bib64","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.biocel.2022.106230_bib65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage\u2013inducing or repair\u2013compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"21","key":"10.1016\/j.biocel.2022.106230_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218273","article-title":"Targeting DNA damage response in prostate and breast cancer","volume":"21","author":"Wengner","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biocel.2022.106230_bib67","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.euo.2019.12.003","article-title":"Rare germline pathogenic mutations of DNA repair genes are most strongly associated with grade group 5 prostate cancer","volume":"3","author":"Wu","year":"2020","journal-title":"Eur. Urol. Oncol."},{"issue":"20","key":"10.1016\/j.biocel.2022.106230_bib68","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1007\/s00018-014-1666-4","article-title":"Functional interplay between ATM\/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress","volume":"71","author":"Yan","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.biocel.2022.106230_bib69","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"issue":"15","key":"10.1016\/j.biocel.2022.106230_bib70","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1158\/0008-5472.CAN-19-0761","article-title":"Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy","volume":"79","author":"Zhang","year":"2019","journal-title":"Cancer Res."}],"container-title":["The International Journal of Biochemistry & Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272522000759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272522000759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:22:08Z","timestamp":1761204128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1357272522000759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":70,"alternative-id":["S1357272522000759"],"URL":"https:\/\/doi.org\/10.1016\/j.biocel.2022.106230","relation":{},"ISSN":["1357-2725"],"issn-type":[{"value":"1357-2725","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer","name":"articletitle","label":"Article Title"},{"value":"The International Journal of Biochemistry & Cell Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biocel.2022.106230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106230"}}